Update 'Essential blood testing in the patient using androgenic anabolic steroids: a clinical practice guideline for primary care'

1 month ago · 63d313ec3b
commit 63d313ec3b
1 changed files with 7 additions and 0 deletions
--- a/Essential-blood-testing-in-the-patient-using-androgenic-anabolic-steroids%3A-a-clinical-practice-guideline-for-primary-care.md
+++ b/Essential-blood-testing-in-the-patient-using-androgenic-anabolic-steroids%3A-a-clinical-practice-guideline-for-primary-care.md
@ -0,0 +1,7 @@
 <br>
 <br>However, as I and others pointed out, there were insufficient data from clinical trials at that time to permit any major conclusions about the role of androgen replacement in the treatment of age-related physiological changes (5). However, the approval of a transdermal [buy testosterone online no prescription](https://thefusionflix.com/@rubenlowrie49?page=about) delivery system in the form of a gel meant that [buy testosterone gel](https://www.shlakoblock.com/joycelynhogben) could now be administered easily, conveniently, and in a pain-free manner (3). For decades, the only method of delivering [testosterone price](https://suprasage.com/tvafausto28933) was through a deep, painful intramuscular injection every two weeks. When prescribing trends are compared between countries, it is evident that this increase in [testosterone purchase](https://lovcam.mydaddyonline.in/@jadao517486035) use was most marked in the United States, with relatively little change in the United Kingdom (1).
 TRT’s potential impact on blood lipid and lipoprotein levels is still debated . Intriguingly, compared to the placebo, HDL levels significantly decreased after TRT. Similarly, the Si Hyun Kim et al. meta-analysis from 2021 showed that TRT significantly reduced total cholesterol compared to a placebo. Nonetheless, a decrease in triglyceride levels and increased HDL cholesterol were found in 14 trials. Excluding the studies individually from the pooled analysis had no effect on the in-study heterogeneity.
 Although some studies suggested a potential effect of TRT directly on glucose metabolism and glycemic control 17,18,19, evidence in this regard is still limited. Anyway, a lot of studies confirmed the role of hypogonadism in considering itself as a cardiovascular risk factor . In addition, a recent meta-analysis demonstrated that TRT do not increase the risk of cardiovascular diseases , particularly if the comorbidities are well controlled . You don’t get aromatization to estrogen, and they also have much more negative effects on the lipid profile with very low HDL levels. Given the bidirectional relationship between testosterone and both obesity and insulin resistance, a holistic approach focused on healthy lifestyle behaviors should always be encouraged when managing a hypogonadal male. The decision to prescribe should be guided by severity of testosterone deficiency, burden of symptoms, and presence of comorbid illness.
 As there were no data on testosterone therapy reported by Holmboe et al , a causal relationship could not be established. Several longitudinal studies have shown that low levels of TT and FT independently predict the later development of T2DM or metabolic syndrome 12,13,14,15,16,17,18. In a study of 1,413 men, those in the first (lowest) tertile of low free [testosterone order](https://botdb.win/wiki/User:LinneaSwart467) (FT) and TT were four times more likely to have diabetes than those in the third tertile of low TT and FT .
 There is also a dearth of data evaluating the safety of [buy testosterone online without prescription](https://git.sskuaixiu.com/fideliaoxq479) therapy in men treated with radiation therapy (RT). Product labels for all [testosterone online pharmacy](http://125.229.107.240:3000/dellaparkman4/gitea.wgqcd.com9957/wiki/15-Foods-That-Increase-Testosterone-Levels-Naturally) formulations explicitly state that their use is contraindicated in men with a history of prostate cancer, which results from Huggins' precept that [purchase testosterone](http://74.48.174.77:3000/bellcollier847) therapy feeds prostate cancer cell proliferation. A total of 651 men (mean age 62.9 years) received oral, transdermal, or IM [buy testosterone pills](http://8.130.135.159:3000/aracelisfranci), while 433 men received placebo for a period of 12 weeks to 36 months. Studies were ineligible if they used supra-physiologic levels of testosterone or  [git.suzk.ru](https://git.suzk.ru/charliwkv31119) if participants were using androgens other than [buy testosterone booster](https://gitea.my-intrudair.com/randalq2855095). Since Huggins' work, subsequent research has failed to definitively link testosterone therapy to a progression of prostate cancer in the untreated patient or recurrence in the treated patient. However, an analysis of Huggins' original paper reveals that this assumption was based on a single patient who was cancer and androgen therapy naïve at study onset. The controversy surrounding prostate cancer and testosterone stems from the work of Dr. Charles Huggins who discovered that treating metastatic prostate cancer patients with ADT resulted in cancer remission,341 suggesting that the presence of testosterone would lead to an increased likelihood of prostate cancer development.
 <br>